



GLOBAL BIOANALYSIS CONSORTIUM

Regulated Bioanalysis A Proposed Global Harmonization Process

presented by Dr. S. Ravisankar for GBC
(replacing Dr. Shrinivas Savale
authorized by GBC Steering Committee)

BABE 2012 - Hyderabad



Global Bioanalysis Consortium
On harmonization of bioanalytical guidance

History

2008-2009:

- Loose discussions in multiple BA communities contemplating on the need and added value of harmonized BA guidelines

Dec. 2009 - EBF Conference (Barcelona, Spain)

- Formal request for harmonization from Bioanalytical community
- Acknowledgement by Regulatory Agencies present (FDA & EMA)
- Discussion among international pharmaceutical scientific organizations with a strong stake in bioanalysis: **AAPS, APA, CVG** and **EBF**
- Request Health Authorities to initiate a harmonization process
 - Offer support to Health Authorities for such a process
 - Letter sent to FDA and EMA in February 2010
- Publication as **Open letter** in April 2010 issue of *Bioanalysis*
- Entertain initial idea of forming a Global Bioanalysis Consortium

GBC: History *(cntd)*

Dec. 2009 - EBF Conference

OPEN LETTER

Request for Global Harmonization of the Guidance for Bioanalytical Method Validation and Sample Analysis

Open letter to the bioanalytical community. Sent to the US FDA/European Medicines Agency in February 2010

Philip Timmerman, MSc
Website: www.europeanbioanalysisforum.eu/

EBF



Steve Lowes, PhD
Website: www.aapspharmaceutica.com



Douglas M Fast, PhD
Website: www.appliedpharmaceuticalanalysis.org



Fabio Garofolo, PhD
Website: www.canadianlcmsgroup.com




Apr. 2010 - CVG Workshop (Montreal, Canada)

- Consensus reached among panelists, 5 regulatory agencies and international attendees on how to proceed with the Global Harmonization of Bioanalytical Guidances: institution of a **Global Bioanalytical Consortium**
- Agreement on the main characteristic of a **Global Bioanalytical Guidance**:
 - **Should be science driven**
 - **Should include rationale behind each requirement to prevent “box checking”**
 - **Should look at global picture, not local issues**
 - **Should NOT be a prescriptive guidance**
 - **Must get buy-in from all the countries**




Which Harmonization Teams?

Overview



Which Harmonization Teams ?



SC Sponsorship of Harmonization Teams

<u>Team Leaders</u>	<u>SC Sponsor</u>	<u>Team Leaders</u>	<u>SC Sponsor</u>
A1: Surendra Bansal A2: Steve Lowes A4: Joseph Bower A6: Nico van den Merbel A11: Russ Weiner	Philip Timmerman Daniel Tang Shinobu Kudoh	L1: Marian Kelley L2: Lauren Stevenson L3: Sherri Dudal L4: Lindsay King L5: Scott Davis L6: Jeff Sailstad	Michaela Golob Fabio Garofolo Binodh DeSilva
A3: Ray Briggs A5: Mike Redrup A7: Eric Fluhler A8: Tom Verhaeghe	Peter van Amsterdam Shrinivas Savale	A9: Chad Briscoe A10: Bob Bethem/ Chad Ray S1: Douglas Fast S2: Eric Woolf S3: Stuart McDougall	Rafael Barrientos Mark Arnold

Operating committees: HT-L

A1: Surendra Bansal

A2: Steve Lowes

A3: Ray Briggs

A4: Joseph Bower

A5: Mike Redrup

A6: Nico van den Merbel

A7: Eric Fluhler

A8: Tom Verhaeghe

A9: Chad Briscoe

A10: Bob Bethem

A11: Russell Weiner

L1: Marian Kelley

L2: Lauren Stevenson

L3: Sherri Dudal

L4: Lindsay King

L5: Scott Davis

L6: Jeff Sailstad

S1: Douglas Fast

S2: Eric Woolf

S3: Stuart Mc Dougall

Harmonization Team Objectives

HT Leaders Objectives

- Remove concepts of company or region from your thinking - you're leading a global effort.
- Facilitate discussion, don't push your personal agenda

Teams are to develop science-based best practices

- Recognize that consensus may not be possible. People with different views will spark vigorous discussion.
- Prevent bullying by the loudest voice. Allow and stimulate less extrovert people to share their opinion and experience
- Recognize that some governments /regions may have regulations that are outdated or inconsistent with a science-based approach. Be prepared to defend proposals that conflict with existing regulations.

80:20 Rule

- Not all items within the Scope of the Team need to be redone, in fact 80% may already have industry-regulatory consensus

HT activities

Compile regional information on regulations and practices related to the Team's scope

- Share regulations with other Team
- A lot of prework has been done

Evaluate scope list to categorize those that:

- Are fully agreed to
- Are generally agreed to
- Have no agreement



HT activities

- For those that are **agreed to** write science-based language as proposed position
- For those that are **generally agreed to**, discuss differences and develop science-based position, write science-based language as proposed position
- For those that are **not generally agreed to**, prioritize the list to enable discussion on those with the greatest impact to the bioanalytical community
 - Have internal team discussions and where possible, develop recommendations
 - Where no consensus is achieved, provide arguments on both sides
 - Utilize GBC SC and other HT leaders for input

Team members should reach back to regional organizations for input

- Query regional organization membership on positions on a topic(s)
- Coordinate across Teams. Regional memberships will lose interest if frequently bombarded with requests.




HT activities

Proposals and outcome

- Write proposals in a clear and concise manner that are suitable for publication, include references to existing literature and regulations
 - As noted above, where proposal conflicts with existing regulations, additional details and discussion may be needed
- Create slide deck for communication of proposals that go into greater depth and may contain data. This will be foundation of
 - Presentations at regional meetings
 - Presentation at international meeting
 - Publications in international journals
 - Note: timing of publications in relation to international meeting
 - *Targeting International meeting in last week of Sept 2012 – venue selection in EU is ongoing*
- Where no consensus is achieved, provide arguments on both sides



Proposed way forward



S1: Small molecule – Specific run acceptance

Team members:

Team lead

- Douglas Fast
Douglas.Fast@covance.com NA

Other members

- Maristela Andraus LA
- Matt Barfield EU
- Michael Blackburn EU
- Ben Gordon EU
- David Hoffman NA
- Noriko Inoue APAC
- Amy LaPaglia NA
- Richard LeLacheur NA
Deputy Team Lead
- Gabriel Marcelin Jimenez LA
- Scott Reuschel NA
- Ravi Sankar APAC

In scope:

• During validation

- Linearity, accuracy, precision
- Calibration curve range and QC placement
- Selection of regression analysis model (linear, quadratic, weighting)
- Criteria for individual runs and overall acceptance
- Validation of plasma blank samples
- Cross validation of anticoagulants and counterions

• During samples analysis

- Individual run acceptance
- Internal standard criteria
- Carryover
- Positive control or predose samples
- Anomalous sample results on run acceptance
- System suitability testing
- Sample and run reinjection
- System conditioning

Interdependencies with other teams:

- A2, A7, A8, A9, L1, S2, S3

Out of scope:

S3: Chromatographic Run Quality Assessment

Team members:

Team lead

- Stuart McDougall EU
stuart.mcdougall@covance.com

Other members

- Ravi Kumar Trivedi APAC
- Ravi Sankar APAC
- Chris Holliman NA
- Hollie Barton NA
- John Dunn NA
- Ray Farmen NA
- Katja Heinig EU
- Liz Thomas EU
- Maria Francesca Riccio LA
- Junji Komaba APAC

In scope

- All analytes giving a quantitative chromatographic response
- Chromatographic approaches (primarily LC)
- Chromatographic detection (primarily MS)
- Calibration and maintenance of chromatographic systems
- Signal to Noise
- Resolution & selectivity
- Peak shape
- SST
- Data sampling
- Peak smoothing & peak filtering
- Internal Standard response criteria
- General integration parameters (not vendor specific)
- Integration process (automated, semi-automated, manual)
- Reintegration (post regression)
- Chromatographic data review
- Audit trail (integration & reintegration)

Interdependencies with other teams

- S1 Small molecule specific run acceptance (Run acceptance, IS acceptance criteria & SST)
- S2 Small molecule specific assay operation (sensitivity, specificity and selectivity)
- A9 - Analytical instrument qualification (calibration and maintenance)
- A1 - Scope and regulations (21CFR11, audit trail, glossary of terms)

Out of scope

- Specific integration parameters (vendor)
- Regression slope
- Instrument qualification



Thank You



Acknowledgements

- The GBC Founding Members
- The GBC Steering Committee
- The Harmonization Team leaders and members